InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,631.22
(
0.28%
)
US TECH 100
19,887.60
(
0.48%
)
Dow Jones
40,211.72
(
0.53%
)
Brent Oil
84.34
(
-0.30%
)
Bitcoin
64,266.68
(
5.75%
)
Post# of 252605
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120052
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 214563

Tuesday, 10/24/2017 5:03:56 PM

Tuesday, October 24, 2017 5:03:56 PM

Post# of 252605
I have FY1Q18* breakeven, not counting milestone payments, at about $250M of Mavyret sales. Even assuming no contribution (yet) from the EU and Japan, ABBV needs to treat fewer than 10K US patients during the quarter to hit that number.

*Calendar 4Q17.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up